复星医药：公司与美国梯瓦就在研药物TEV-56278的开发合作如期推进

Core Viewpoint - The company is progressing as planned in its strategic collaboration with Teva Pharmaceuticals on the development of the drug TEV-56278, which is currently in the preclinical stage within the licensed region [1] Group 1 - The collaboration with Teva Pharmaceuticals is ongoing and on schedule [1] - The drug TEV-56278 is still in the preclinical phase [1] - The company will disclose any significant developments in accordance with the listing rules [1]